Literature DB >> 32016390

Magnetic resonance imaging for diagnosis of recurrent ipsilateral deep vein thrombosis.

Lisette F van Dam1, Charlotte E A Dronkers1,2, Gargi Gautam3, Åsa Eckerbom3, Waleed Ghanima4,5, Jostein Gleditsch6, Anders von Heijne3, Herman M A Hofstee2, Marcel M C Hovens7, Menno V Huisman1, Stan Kolman8, Albert T A Mairuhu9, Mathilde Nijkeuter10, Marcel A van de Ree8, Cornelis J van Rooden11, Robin E Westerbeek12, Jan Westerink10, Eli Westerlund3, Lucia J M Kroft13, Frederikus A Klok1.   

Abstract

The diagnosis of recurrent ipsilateral deep vein thrombosis (DVT) is challenging, because persistent intravascular abnormalities after previous DVT often hinder a diagnosis by compression ultrasonography. Magnetic resonance direct thrombus imaging (MRDTI), a technique without intravenous contrast and with a 10-minute acquisition time, has been shown to accurately distinguish acute recurrent DVT from chronic thrombotic remains. We have evaluated the safety of MRDTI as the sole test for excluding recurrent ipsilateral DVT. The Theia Study was a prospective, international, multicenter, diagnostic management study involving patients with clinically suspected acute recurrent ipsilateral DVT. Treatment of the patients was managed according to the result of the MRDTI, performed within 24 hours of study inclusion. The primary outcome was the 3-month incidence of venous thromboembolism (VTE) after a MRDTI negative for DVT. The secondary outcome was the interobserver agreement on the MRDTI readings. An independent committee adjudicated all end points. Three hundred five patients were included. The baseline prevalence of recurrent DVT was 38%; superficial thrombophlebitis was diagnosed in 4.6%. The primary outcome occurred in 2 of 119 (1.7%; 95% confidence interval [CI], 0.20-5.9) patients with MRDTI negative for DVT and thrombophlebitis, who were not treated with any anticoagulant during follow-up; neither of these recurrences was fatal. The incidence of recurrent VTE in all patients with MRDTI negative for DVT was 1.1% (95% CI, 0.13%-3.8%). The agreement between initial local and post hoc central reading of the MRDTI images was excellent (κ statistic, 0.91). The incidence of VTE recurrence after negative MRDTI was low, and MRDTI proved to be a feasible and reproducible diagnostic test. This trial was registered at www.clinicaltrials.gov as #NCT02262052.
© 2020 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32016390     DOI: 10.1182/blood.2019004114

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

1.  Cost-effectiveness of magnetic resonance imaging for diagnosing recurrent ipsilateral deep vein thrombosis.

Authors:  Lisette F van Dam; Wilbert B van den Hout; Gargi Gautam; Charlotte E A Dronkers; Waleed Ghanima; Jostein Gleditsch; Anders von Heijne; Herman M A Hofstee; Marcel M C Hovens; Menno V Huisman; Stan Kolman; Albert T A Mairuhu; Mathilde Nijkeuter; Marcel A van de Ree; Cornelis J van Rooden; Robin E Westerbeek; Jan Westerink; Eli Westerlund; Lucia J M Kroft; Frederikus A Klok
Journal:  Blood Adv       Date:  2021-03-09

2.  Time-Restricted Salutary Effects of Blood Flow Restoration on Venous Thrombosis and Vein Wall Injury in Mouse and Human Subjects.

Authors:  Wenzhu Li; Chase W Kessinger; Makoto Orii; Hang Lee; Lang Wang; Ido Weinberg; Michael R Jaff; Guy L Reed; Peter Libby; Ahmed Tawakol; Peter K Henke; Farouc A Jaffer
Journal:  Circulation       Date:  2021-01-15       Impact factor: 29.690

Review 3.  Predicting the Risk of Recurrent Venous Thromboembolism: Current Challenges and Future Opportunities.

Authors:  Hannah Stevens; Karlheinz Peter; Huyen Tran; James McFadyen
Journal:  J Clin Med       Date:  2020-05-22       Impact factor: 4.241

4.  Safety of using the combination of the Wells rule and D-dimer test for excluding acute recurrent ipsilateral deep vein thrombosis.

Authors:  Lisette F van Dam; Gargi Gautam; Charlotte E A Dronkers; Waleed Ghanima; Jostein Gleditsch; Anders von Heijne; Herman M A Hofstee; Marcel M C Hovens; Menno V Huisman; Stan Kolman; Albert T A Mairuhu; Mathilde Nijkeuter; Marcel A van de Ree; Cornelis J van Rooden; Robin E Westerbeek; Jan Westerink; Eli Westerlund; Lucia J M Kroft; Frederikus A Klok
Journal:  J Thromb Haemost       Date:  2020-07-21       Impact factor: 5.824

5.  In vivo real-time red blood cell migration and microcirculation flow synergy imaging-surveyed thrombolytic therapy with iron-oxide complexes.

Authors:  Fei Ye; Bei Zhang; Lige Qiu; Yunrui Zhang; Yang Zhang; Jian Zhang; Qingliang Zhao; Ligong Lu; Zhenlin Zhang
Journal:  Mater Today Bio       Date:  2022-08-26

6.  Safety of a strategy combining D-dimer testing and whole-leg ultrasonography to rule out deep vein thrombosis.

Authors:  Synne G Fronas; Camilla T Jørgensen; Anders E A Dahm; Hilde S Wik; Jostein Gleditsch; Nezar Raouf; René Holst; F A Klok; Waleed Ghanima
Journal:  Blood Adv       Date:  2020-10-27

7.  High Signal Intensity on Diffusion-Weighted Images Reflects Acute Phase of Deep Vein Thrombus.

Authors:  Toshihiro Gi; Yasuyoshi Kuroiwa; Atsushi Yamashita; Yuko Mizutani; Taketoshi Asanuma; Tosiaki Miyati; Kazunari Maekawa; Murasaki Aman; Takuroh Imamura; Yujiro Asada
Journal:  Thromb Haemost       Date:  2020-08-03       Impact factor: 5.249

Review 8.  Black-Blood Contrast in Cardiovascular MRI.

Authors:  Markus Henningsson; Shaihan Malik; Rene Botnar; Daniel Castellanos; Tarique Hussain; Tim Leiner
Journal:  J Magn Reson Imaging       Date:  2020-10-19       Impact factor: 5.119

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.